Beam Therapeutics Inc. (BEAM) Stock Analysis

Q: What is the BEAM stock price target?

Take-profit $45.96 (+64.6% upside). Prior stop was $26.29.

Q: What are the risks of investing in BEAM?

Concentration risk — Pipeline: risto-cel; Quality below floor (2.2 < 4.0); Quality below floor (2.2 < 4.0); Momentum score 3.0/10 — below 4.5 minimum.

Q: Is BEAM overvalued or undervalued?

Beam Therapeutics Inc. trades at a P/E of N/A (forward -5.8). TrendMatrix value score: 5.4/10. Overall verdict: Sell.

Q: What do analysts say about BEAM?

25 analysts cover BEAM with a consensus score of 4.3/5. Average price target: $51.

SellModerate ConfidenceUpdated 3 days ago (May 18, 2026, 1:11 AM ET)

Healthcare · Biotechnology

$27.99+64.6% A.UpsideScore 4.6/10#127 of 157 Biotechnology

QualityF-score4 / 9FCF yield-8.13%

Stop $26.29Target $45.96(analyst − 10%)A.R:R 4.3:1

Analyst target$51.07+82.4%15 analysts

$45.96our TP

$27.99price

$51.07mean

$80

Sell if holding. Engine safety override at $27.99: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 4.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 32%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.6/10, moderate confidence.

Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Recent Developments — Beam Therapeutics Inc.

Latest news

Beam Therapeutics Presented Clinical Data From Phase 1/2 Trial For BEAM-302 Treatment For Alpha-1 Antitrypsin Deficiency — benzinga May 18, 2026 positive
Bernstein Maintains Outperform on Beam Therapeutics, Lowers Price Target to $39 — benzinga May 13, 2026 positive
Beam Therapeutics To Present Updated Data From Phase 1/2 Trials For Sickle Cell Disease Treatment At European Hematology — benzinga May 12, 2026 positive
Beam Therapeutics Q1 EPS $(0.91) Beats $(1.09) Estimate, Sales $31.738M Beat $10.977M Estimate — benzinga May 7, 2026 positive
Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth — benzinga Apr 29, 2026 positive

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards

No bull case signals

Risks

Concentration risk — Pipeline: risto-cel

Quality below floor (2.2 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-5.8

Mkt Cap$2.9B

EV/EBITDA-5.2

Profit Mgn-40.2%

ROE-5.8%

Rev Growth324.9%

Beta2.26

DividendNone

Rating analysts25

Quality Signals

Piotroski F4/9MoatNarrow

Concentration Risks(10-K Item 1A)

HIGHpipelineristo-cel
10-K Item 1: 'We expect to submit a biologics license application, or BLA, for risto-cel as early as year-end 2026'

Material Events(8-K, last 90d)

2026-03-05Item 1.02MEDIUM
Mutual termination of License Agreement with Bio Palette Co., Ltd. effective March 2, 2026, in connection with Bio Palette's planned dissolution. Standby License Agreement with Kobe University simultaneously activated, granting Beam the same exclusive license scope with no IP gap.
SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value5.415%0.81

Quality2.215%0.33

Growth5.015%0.75

Momentum3.010%0.30

Sentiment8.710%0.87

Insider Activity3.310%0.33

Peer Rank4.410%0.44

Technical Setup7.45%0.37

Risk Profile2.45%0.12

Catalyst6.55%0.33

Overall (Σ contributions)4.65

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static

Roe

0.0

Roa

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

4.4

Current Ratio

5.0

Moat

5.8

Cash-burning: FCF -142% of revenueQuality concerns

Volatile — 7.5% daily ATR makes tight stops impractical. Position-size conservatively.static

Volatility

0.0

Short Interest

0.3

Days To Cover

0.3

Beta

2.5

Debt Equity

9.1

High short interest justified: 32%Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd

0.0

Obv

1.0

Volume

2.7

Rsi

5.5

Ma Position

6.0

Volume distribution (falling OBV)Above 200-day MA

GatesMomentum 3.0<4.5A.R:R 4.3 ≥ 1.5Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY 79d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive

RSI

46 · Neutral

↓ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $27.10Resistance $34.38

Price Targets

$26

$46

A.Upside+64.2%

A.R:R4.3:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (2.2 < 4.0)

! Momentum score 3.0/10 — below 4.5 minimum

Earnings

3/4 beats

Next Earnings2026-08-04 (79d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is BEAM stock a buy right now?

Sell if holding. Engine safety override at $27.99: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 4.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 32%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $26.29. Score 4.6/10, moderate confidence.

What is the BEAM stock price target?

Take-profit target: $45.96 (+64.6% upside). Prior stop was $26.29. Stop-loss: $26.29.

What are the risks of investing in BEAM?

Concentration risk — Pipeline: risto-cel; Quality below floor (2.2 < 4.0).

Is BEAM overvalued or undervalued?

Beam Therapeutics Inc. trades at a P/E of N/A (forward -5.8). TrendMatrix value score: 5.4/10. Verdict: Sell.

What do analysts say about BEAM?

25 analysts cover BEAM with a consensus score of 4.3/5. Average price target: $51.

What does Beam Therapeutics Inc. do?Beam Therapeutics is a clinical-stage biotechnology company developing precision base editing medicines for genetic...

Beam Therapeutics is a clinical-stage biotechnology company developing precision base editing medicines for genetic diseases, with lead programs risto-cel (Phase 1/2 sickle cell disease, BLA expected late 2026) and BEAM-302 (Phase 1/2 for alpha-1 antitrypsin deficiency). The company operates a 100,000 sq ft cGMP manufacturing facility in Research Triangle Park, NC and has no approved products or material revenue. Multiple programs are advancing in parallel targeting rare hematologic and genetic conditions.